Characterization of recombinant IFN β-1b and elucidation of its role as a therapy/regimen against Multiple Sclerosis

Multiple sclerosis (MS) is a metabolically dependent neurodegenerative disorder caused by persistent axonal loss of the brain and spinal cord. It is the most prevalent cause of non-traumatic neurological disability among young adults, especially females, in Western countries. DMTs and cost-effective pharmacotherapies can help patients address their condition by lowering their risk of relapse, postponing disability, and/or having fewer brain lesion loads. Interferon is one of the first-line therapies to treat MS patients in India. This project addresses the desire for developing novel therapeutic regimens and their essential role in improving patients’ health.

Ayesha Aiman
Ayesha Aiman
PMRF Research Scholar